OSE Immunotherapeutics is Pleased to Announce the Continuation of its ... Ose immuno : L'essai sur le vaccin anti-Covid d'OSE Immuno suspendu ... OSE Immunotherapeutics to Present New Clinical and Preclinical Data at ... OSE Immunotherapeutics Presented New Translational Data on Tedopi® and ... NANTES, France, December 13, 2021--OSE Immuno is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis OSE-FR: OSE Immunotherapeutics SA - Stock Price, Quote and News - CNBC OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Tedopi (formerly known as OSE-2101), is a cancer vaccine being developed by OSE Immunotherapeutics for the treatment of certain types of lung cancer. Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient ... The company's immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto . OSE Immunotherapeutics to Host Today a Virtual "Immuno-Oncology R&D Day" OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. Tedopi (OSE-2101) - Immuno-Oncology News OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T. Its balanced. Its balanced. Initiation of the Phase 1 clinical expansion trial triggers a €10 million milestone payment from Boehringer Ingelheim to OSE Immunotherapeutics.The trial is being conducted in advanced hepatocellular carcinoma and head and neck cancer patients in combination in particular with anti-PD-1 antibody Ezabenlimab.